LEXEO Therapeutics
LEXEO Therapeutics
Brand Strategy
Website Development
Messaging
Investor Communications
Founded in 2018 by pioneers in gene therapy, Lexeo Therapeutics quickly emerged as a noteworthy contender. By 2023, the company had made remarkable progress in its pipeline, setting the stage for a potential IPO. Lexeo’s rapid evolution required a comprehensive brand evaluation to capture what makes them unique, position the company as a strong investment for institutional and retail investors, and prepare Lexeo for its next chapter as a publicly traded entity.
To develop a credible and compelling narrative for Lexeo, we engaged a wide range of stakeholders – from leadership, front-line staff and new hires to investors, board members, physicians, and key opinion leaders. Working closely with Lexeo executives, we employed both strategic and creative exercises to establish the core elements that would underpin the company’s evolved brand, messaging, and content strategy.
The foundation of Lexeo's new brand strategy is captured in the concept of "Changing health and healthcare for good." This carefully crafted message reflects Lexeo's genuine commitment to individual wellbeing and their ambitious drive to innovate novel approaches for genetic medicine treatments that have the potential to transform how all medicine is developed.
We implemented a two-step communications strategy to support Lexeo’s IPO. Initially, we simplified their scientific narrative, linking it to the company’s potential for systemic impact and enhanced commercial success. This included providing essential content for Lexeo’s S1 documentation, roadshow presentations, and corporate website, ensuring a cohesive investor narrative during the pre-IPO phase.
Simultaneously, we crafted a broader, evergreen brand narrative that powerfully conveys Lexeo’s ambitions. This included developing a comprehensive communications toolkit that allows Lexeo to articulate a purpose-driven narrative to a wider audience than ever before.
Lexeo Therapeutics successfully launched its initial public offering on NASDAQ in November 2023, raising gross proceeds of over $100 million. A few months later in March 2024, Lexeo closed an additional round of oversubscribed equity financing at a share price approximately 50% than the IPO price - impressive achievements that successfully launched Lexeo forward in their fight to change health and healthcare for good.
“Rarefy not only identified what makes Lexeo unique but also helped us express our brand more powerfully than I anticipated. The shifts Rarefy facilitated added immense value throughout the IPO process, clarifying our strategy and positioning with investors. Their team was hands-on from day one, adapting as needed while keeping us focused on our boldest ambitions.”
Nolan Townsend, CEO, Lexeo Therapeutics
hello@rarefyco.com
